Fig. 4: AAV-EGFP-PFFNB2 reduces α-syn pathology induced by PFF in vivo.
From: α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice
a Timeline of in vivo experiments. Intraventricular injection of AAV was performed in neonatal mouse brains. These mice were then stereotactically injected with α-syn PFF at 2-months old, and then sacrificed 1 month after α-syn PFF injection. b, c Immunostaining of pS129 (red) normalized by Hoechst (blue). The green signal indicates the expression level of EGFP or EGFP-PFFNB2 fusion protein in the cortex. Scale bars, 50 μm. d, e Quantification of pS129 immunostaining in the cortex. Data are the means ± SEM, n = 4 mice per group, P values were determined by two-sided Student’s t test. (AAV-EGFP vs. AAV-EGFP-PFFNB2, P = 0.0004). ***P < 0.001. Source data are provided as a Source Data file.
